Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside: A novel synergistic option for glioblastoma therapy

Julien Fleurence 1 Meriem Bahri 1 Sophie Fougeray 1, 2 Sébastien Faraj 3 Sarah Vermeulen 3 Émilie Pinault 4 Fanny Geraldo 5 Lisa Oliver 5 Joëlle Véziers 6, 7, 8 Pierre Marquet 9 Marion Rabé 5 Catherine Gratas 5 François Vallette 5, 10 Claire Pecqueur 1 François Paris 1, 10 Stéphane Birklé 1, 2, *
* Corresponding author
1 CRCINA - Département ONCO - Equipe 14 - Endothelium radiobiology and targeting
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
2 Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
3 CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
4 BISCEm - Biologie Intégrative Santé Chimie Environnement
GEIST - Institut Génomique, Environnement, Immunité, Santé, Thérapeutique
5 CRCINA - Département ONCO - Equipe 9 - Apoptosis and tumor progression -ATP
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
6 RMeS - Regenerative Medicine and Skeleton research lab
7 P2R - INSERM UMS016/CNRS UMS3556/UN FED4203 - Plateforme "Production de protéines recombinantes"
SFR François Bonamy - Structure fédérative de recherche François Bonamy
8 Pôle hospitalo-universitaire PHU4 - OTONN - Ostéo-articulaire - Tête et cou - Odontologie - Neurochirurgie - Neurotraumatologie [CHU Nantes]
9 IPPRITT - Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation
10 LabCT - Laboratoire de Biologie des Cancers et de Théranostic [St Herblain, Nantes]
Abstract : Stem cell chemo-resistance is still challenging the efficacy of the front-line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti-O-acetyl-GD2 adjuvant immunotherapy controls glioma stem-like cell-driven chemo-resistance. Using patient-derived glioblastoma cells we found that glioma stem-like cells over-expressed O-acetyl-GD2. As a result, monoclonal antibody 8B6 immunotherapy significantly increased temozolomide genotoxicity and tumor cell death in vitro by enhancing temozolomide tumor uptake. Furthermore, the combination therapy decreased the expression of the glioma stem-like cell markers CD133 and Nestin and compromised glioma stem-like cell self-renewal capabilities. When tested in vivo, adjuvant 8B6 immunotherapy prevented the extension of the temozolomide-resistant glioma stem-like cell pool within the tumor bulk in vivo and was more effective than the single agent therapies. This is the first report demonstrating that anti-O-acetyl-GD2 monoclonal antibody 8B6 targets glioblastoma in a manner that control temozolomide-resistance driven by glioma stem-like cells. Together our results offer a proof of concept for using anti-O-acetyl GD2 reagents in glioblastoma to develop more efficient combination therapies for malignant gliomas. This article is protected by copyright. All rights reserved.
Keywords : brain cancer cancer immunotherapy oncology
Document type :
Journal articles
Complete list of metadatas

Cited literature [75 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02168202
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, June 28, 2019 - 2:56:21 PM
Last modification on : Tuesday, January 21, 2020 - 11:42:15 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

UNILIM | UNAM | CNRS | CRCINA | IPPRITT | UNIV-NANTES | GEIST | UNIV-ANGERS | RMES

Citation

Julien Fleurence, Meriem Bahri, Sophie Fougeray, Sébastien Faraj, Sarah Vermeulen, et al.. Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside: A novel synergistic option for glioblastoma therapy. International Journal of Cancer, Wiley, In press, Epub ahead of print. ⟨10.1002/ijc.32533⟩. ⟨inserm-02168202⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

161

Contact

Informations

CCSD